Dysregulation in T helper 1/T helper 2 cytokine ratios in patients with multiple myeloma

References

• Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence of a multistep transformation process. Blood 1998;91:3–21.
   PubMed Web of Science ®Google Scholar
• Klein B, Bataille R. Cytokine network in human multiple myeloma. Hematol Oncol Clin North Am 1992;6:273–284.
   PubMed Web of Science ®Google Scholar
• Lauta VM. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications. Cancer 2003;97:2440–2452.
   PubMed Web of Science ®Google Scholar
• Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 2004;4:12–22.
   Web of Science ®Google Scholar
• Elssser-Belie U, von-Kleist S, Gallati H. Evaluation of a test system for measuring cytokine production in human whole blood cell cultures. J Immunol Methods 1991;139:191–195.
   PubMed Web of Science ®Google Scholar
• Lucey DR, Clerece M, Shearer GM. Type 1 and type 2 cytokines dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin Microbiol Rev 1996;9:533–562.
   Google Scholar
• Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008;8:299–308.
   PubMed Web of Science ®Google Scholar
• Mosman TR, Cherwinski H, Bond MW, Gieldlin MA, Coffman L. Two types of murine T cell clone. Defintion according to profiles of lymphokine activities and secreted proteins. J Immunol 1986;136:2348–2357.
   Google Scholar
• Romagnani S. Human Th1 and Th2 subsets: doubt no more. Immunol Today 1991;12:256–257.
   PubMedGoogle Scholar
• Paliard X, de Waal Malefijt R, Yssel H, et al Simultaneous production of IL-2, IL-4, and IFN-γ by activated human CD4+ and CD8+ T cell clones. J Immunol 1988;141:849–855.
   PubMed Web of Science ®Google Scholar
• Mosman TR, Coffmann RL Heterogeneity of cytokine secretion patterns and functions of helper T-cells. Adv Immunol 1989;46:111–147.
   PubMed Web of Science ®Google Scholar
• Mori T, Takada R, Watanabe R, Okamoto S, Ikeda Y. T-helper (Th)1/2 imbalance in patients with previously untreated B-cell diffuse large cell lymphoma. Cancer Immunol Immunother 2001;50:566–568.
   PubMed Web of Science ®Google Scholar
• Zhang XL, Komada Y, Chipeta J, et al Intracellular cytokine profile of T cells from children with acute lymphoblastic leukemia. Cancer Immunol Immunother 2000;49:165–172.
   PubMed Web of Science ®Google Scholar
• Janeway CA Jr, Travers P. Immunobiology: the immune system in health and disease. London: Garland/Churchill Livingstone, 1997.
   Google Scholar
• Mosmann TR, Coffman RL. Two types of mouse T helper cell clone implication for immune regulation. Immunol Today 1987;8:223–226.
   PubMedGoogle Scholar
• Sharma A, Rajappa M, Saxena A, Sharma M. Cytokine profile in Indian women with cervical intraepithelial neoplasia and cancer cervix. Int J Gynecol Cancer 2007;17:879–885.
   PubMed Web of Science ®Google Scholar
• Klein B, Zhang XG, Lu ZY, Bataille R. Interleukin-6 in human multiple myeloma. Blood 1995;85:863–872.
   PubMed Web of Science ®Google Scholar
• Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996;383:787–793.
   PubMed Web of Science ®Google Scholar
• Romagnani S. Th1 and Th2 in human diseases. Clin Immunol Immunopathol 1996;80:225–235.
   PubMedGoogle Scholar
• Frassanito MA, Cusmai A, Dammacco F. Deregulated cytokine network and defective Th1 immune response in multiple myeloma. Clin Exp Immunol 2001;125:190–197.
   PubMed Web of Science ®Google Scholar
• Pisa P, Stenke L, Bernell P, Hansson M, Hast R. Tumor necrosis factor-alpha and interferon-gamma in serum of multiple myeloma patients. Anticancer Res 1990;10:817–820.
   PubMed Web of Science ®Google Scholar
• Varesio L, Espinoza-Delgado I, Gusella L, et al Role of cytokines in the activation of monocytes. In: Aggarwal BB, Puri RK, editors. Human cytokines: their role in disease and therapy. Cambridge, MA: Blackwell Science; 1995. p 55.
   Google Scholar
• Spicka I, Tomsová Z, Masek Z, Procházka B, Zounar R, Klener P. Urinary excretion of neopterin and plasma levels of interferon gamma in patients with multiple myeloma. Vnitr Lek 1996;42:665–668.
   PubMedGoogle Scholar
• Gherardi RK, Belec L, Soubrier M, et al Overproduction of proinflammatory cytokines imbalanced by their antagonists in POEMS syndrome. Blood 1996;87:1458–1465.
   PubMed Web of Science ®Google Scholar
• Heslop HE, Gottlieb DJ, Bianchi AC, et al In vivo induction of gamma interferon and tumor necrosis factor by interleukin-2 infusion following intensive chemotherapy or autologous marrow transplantation. Blood 1989;74:1374–1380.
   PubMed Web of Science ®Google Scholar
• Cimino G, Avvisati G, Amadori S, et al High serum IL-2 levels are predictive of prolonged survival in multiple myeloma. Br J Haematol 1990;75:373–377.
   PubMed Web of Science ®Google Scholar
• Vacca A, Di Stefano R, Frassanito A, Iodice G, Dammacco F. A disturbance of the IL-2/IL-2 receptor system parallels the activity of multiple myeloma. Clin Exp Immunol 1991;84:429–434.
   PubMed Web of Science ®Google Scholar
• Wang Z, Li D, Yang J. Changes of serum interleukin 2 and soluble interleukin 2 receptor and their clinical significance in multiple myeloma. Zhonghua Zhong Liu Za Zhi 1996;18:439–441.
   PubMedGoogle Scholar
• Famularo G, Giacomelli R, Di Giovanni S, Sacchetti S, Tonietti G. Cytokine production in patients with monoclonal gammapathies. J Clin Lab Immunol 1991;34:63–69.
   PubMedGoogle Scholar
• Sonmez M, Sonmez B, Eren N, Yilmaz M, Karti SS, Ovali E. Effects of interferon-alpha-2a on Th3 cytokine response in multiple myeloma patients. Tumori 2004;90:387–389.
   PubMed Web of Science ®Google Scholar
• Sawamura M, Murakami H, Tsuchiya J. Tumor necrosis factor and interleukin-4 in myeloma cell precursor differentiation. Leuk Lymphoma 1996;21:31–36.
   PubMed Web of Science ®Google Scholar
• Kyrstsonis MC, Dedoussis G, Baxevanis C, Stamatelou M, Maniatis A. Serum interleukin-6 (IL-6) and interleukin-4 (IL-4) in patients with multiple myeloma (MM). Br J Haematol 1996;92:420–422.
   PubMed Web of Science ®Google Scholar
• Kiss TL, Lipton JH, Bergsagel DE, et al Determination of IL6, IL1, and IL4 in the plasma of patients with multiple myeloma. Leuk Lymphoma 1994;14:335–340.
   PubMed Web of Science ®Google Scholar
• Kidd P. Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Altern Med Rev 2003;8:223–246.
   PubMedGoogle Scholar
• Lu ZY, Zhang XG, Rodriguez C, et al Interleukin-10 is a proliferation factor but not a differentiation factor for human myeloma cells. Blood 1995;85:2521–2527.
   PubMed Web of Science ®Google Scholar
• Brown RD, Pope B, Murray A, et al Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-b1 and interleukin-10. Blood 2001;98:2992–2998.
   PubMed Web of Science ®Google Scholar
• Urbaenska-Ryes H, Wiersbowska A, Stepien H, Robak T. Relationship between circulating interleukin-10 (IL-10) with interleukin-6 (IL-6) type cytokines (IL-6, interleukin-11 (IL-11), oncostatin M (OSM)) and soluble interleukin-6 (IL-6) receptor (sIL-6R) in patients with multiple myeloma. Eur Cytokine Netw 2000;11:443–451.
   PubMed Web of Science ®Google Scholar
• Zdzisińska B, Walter-Croneck A, Dmoszyńska A, Kandefer-Szerszeń M. Matrix metalloproteinase and cytokine production by bone marrow adherent cells from multiple myeloma patients. Arch Immunol Ther Exp 2006;54:289–296.
   PubMed Web of Science ®Google Scholar
• Merville P, Rousset F, Bancherau J, Klein B, Bataille R. Serum interleukin-10 in early stage multiple myeloma. Lancet 1992;340:1544–1545.
   PubMed Web of Science ®Google Scholar
• Klouche M, Wilhelm D, Kirchner H. Cytokines, immunoglobulins, and IgG subclasses in patients with IgG plasmacytomas. Immun Infekt 1994;22:149–151.
   PubMedGoogle Scholar
• Rousset F, Garcia E, De France T, et al Interleukin-10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci USA 1992;89:1890–1893.
   PubMed Web of Science ®Google Scholar
• Yi Q, Osterborg A, Bergenbrant S, Lellstedt H, Holm G, Lefvert AK. Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies. Blood 1995;86:3043–3049.
   PubMed Web of Science ®Google Scholar
• Cook G, Campbell JDM, Carr CE, Boyd KS, Franklin IE. Transforming growth factor β from multiple myeloma cells inhibits proliferation and IL-2 responsiveness in T-lymphocytes. J Leukoc Biol 1999;66:981–988.
   PubMed Web of Science ®Google Scholar
• Murakami H, Ogawara H, Hiroshi H. Th1/Th2 cells in patients with multiple myeloma. Hematology 2004;9:41–45.
   PubMedGoogle Scholar
• Ogawara H, Handa H, Yamazaki T, et al High Th1/Th2 ratio in patients with multiple myeloma. Leuk Res 2005;29:135–140.
   PubMed Web of Science ®Google Scholar
• Goswami B, Rajappa M, Sharma M, Sharma A. Inflammation: its role and interplay in the development of cancer, with special focus on gynecological malignancies. Int J Gynecol Cancer 2008;18:591–599.
   PubMed Web of Science ®Google Scholar
• Sharma A, Tripathi M, Satyam A, Kumar L. Study of antioxidant levels in patients with multiple myeloma. Leuk Lymphoma 2009;50:809–815.
   PubMed Web of Science ®Google Scholar
• Sharma A, Rajappa M, Saxena A, Sharma M. Antioxidant status in advanced cervical cancer patients undergoing neoadjuvant chemoradiation. Br J Biomed Sci 2007;64:23–27.
   PubMed Web of Science ®Google Scholar